0001157523-20-000949.txt : 20200630 0001157523-20-000949.hdr.sgml : 20200630 20200630172953 ACCESSION NUMBER: 0001157523-20-000949 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20200630 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200630 DATE AS OF CHANGE: 20200630 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CROSS COUNTRY HEALTHCARE INC CENTRAL INDEX KEY: 0001141103 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HELP SUPPLY SERVICES [7363] IRS NUMBER: 134066229 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-33169 FILM NUMBER: 201003230 BUSINESS ADDRESS: STREET 1: 5201 CONGRESS AVENUE STREET 2: SUITE 100B CITY: BOCA RATON STATE: FL ZIP: 33487 BUSINESS PHONE: 8003472264 MAIL ADDRESS: STREET 1: 5201 CONGRESS AVENUE STREET 2: SUITE 100B CITY: BOCA RATON STATE: FL ZIP: 33487 FORMER COMPANY: FORMER CONFORMED NAME: CROSS COUNTRY INC DATE OF NAME CHANGE: 20010521 8-K 1 a52243705.htm CROSS COUNTRY HEALTHCARE, INC. 8-K

UNITED STATES 
 SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
 
 
 
FORM 8-K
 
 
 
CURRENT REPORT


Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported) June 30, 2020
 graphic
 
 
 
Cross Country Healthcare, Inc.
(Exact name of registrant as specified in its charter)
 
 

Delaware
0-33169
13-4066229
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)
 

5201 Congress Avenue, Suite 100B, Boca Raton, Florida 33487
(Address of Principal Executive Office) (Zip Code)
(561) 998-2232
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class Trading Symbol Name of each exchange on which registered
Common stock, par value $0.0001 per share
CCRN
The NASDAQ Stock Market

 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2).
Emerging growth company
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01   Entry into a Material Definitive Agreement

On June 30, 2020, Cross Country Healthcare, Inc. (the "Company") amended its ABL Credit Agreement dated October 25, 2019 among the Company, substantially all of its wholly-owned subsidiaries, PNC Bank N.A., as lender, and Wells Fargo Bank N.A., as lender and administrative agent. The amended ABL Credit Agreement increases the current aggregate committed size of the asset-based credit facility from $120.0 million to $130.0 million. All other terms, conditions, covenants, and pricing of the ABL Credit Agreement remain the same.

The foregoing description does not purport to be complete and is qualified in its entirety by reference to the full text of the Amended ABL Credit Agreement as filed as Exhibit 10.1 to this Form 8-K.

Item 2.03   Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

The information provided in Item 1.01 of this Current Report on Form 8-K is incorporated into Item 2.03 by reference.

Item 5.02   Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On June 30, 2020 and as part of the registrant’s response to the current economic environment resulting from the COVID-19 pandemic, the Company’s Board of Directors approved a 10% reduction in base salary for the following executive officers: William Burns, EVP and Chief Financial Officer, Buffy White, EVP and Group President Workforce Solutions & Services, Stephen Saville, EVP Operations, and Susan Ball, EVP and General Counsel. The 10% reduction is expected to continue until December 31, 2020, and will not impact other compensation elements such as short-term incentives. Effective July 1, 2020, their new base salaries are as follows: Mr. Burns, $472,500; Ms. White, $387,000; Mr. Saville, $387,000; and Ms. Ball, $378,000.

Item 9.01   Financial Statements and Exhibits
(d) Exhibits

          
Exhibit
Description
 
 
 
 
     
  104.1
Cover Page Interactive Data File (embedded within the Inline XBRL document)


SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 
 
CROSS COUNTRY HEALTHCARE, INC.
 
 
 
 
 
 
 
 
Dated:
June 30, 2020
By:
/s/ William J. Burns
 
 
 
 
Name:  William J. Burns
 
 
 
Title: Executive Vice President and Chief Financial Officer
 
 
 
 

EX-10.1 2 a52243705ex10_1.htm EXHIBIT 10.1
 
 Exhibigt 10.1




AMENDMENT NO. 1 TO ABL CREDIT AGREEMENT
AMENDMENT NO. 1 TO ABL CREDIT AGREEMENT, dated as of June 30, 2020 (this “Amendment No. 1”), is by and among Wells Fargo Bank, National Association, a national banking association, as administrative agent for each member of the Lender Group and the Bank Product Providers (in such capacity, together with its successors and assigns in such capacity, “Agent”), Wells Fargo Bank, National Association, a national banking association, in its capacity as sole lead arranger (in such capacity, together with its successors and assigns in such capacity, the “Lead Arranger”), Wells Fargo Bank, National Association, a national banking association as sole book runner (in such capacity, together with their successors and assigns in such capacity, the “Book Runner”), Wells Fargo Bank, National Association, a national banking association, as collateral agent (in such capacity, together with its successors and assigns in such capacity, “Collateral Agent”), Cross Country Healthcare, Inc., a Delaware corporation (“Parent”), Cejka Search, Inc., a Delaware corporation (“Cejka”), Cross Country Staffing, Inc., a Delaware corporation (“Cross Country Staffing”), Assignment America, LLC., a Delaware limited liability company (“Assignment America”), Travel Staff, LLC, a Delaware limited liability company (“Travel Staff”), Medical Doctor Associates, LLC, a Delaware limited liability company (“Medical Doctor”), OWS, LLC, a Delaware limited liability company (“OWS”), New Mediscan II, LLC, a California limited liability company (“New Mediscan” and together with Parent, Cejka, Cross Country Staffing, Assignment America, Travel Staff, Medical Doctor, OWS and those additional persons that hereafter become parties thereto as Borrowers in accordance with the terms thereof, each, a “Borrower” and individually and collectively, jointly and severally, the “Borrowers”), MDA Holdings, Inc., a Delaware corporation (“MDA Holdings”), Credent Verification and Licensing Services, LLC, a Delaware limited liability company (“Credent Verification” and together with MDA Holdings and those additional persons that hereafter become parties thereto as Guarantors in accordance with the terms thereof, each, a “Guarantor” and individually and collectively, jointly and severally, the “Guarantors”).
W I T N E S S E T H:
WHEREAS, Agent, Lenders, Borrowers and Guarantors have entered into senior secured asset-based revolving credit facility pursuant to which Lenders (or Agent on behalf of Lenders) have made and may make loans and advances and provide other financial accommodations to Borrowers as set forth in the ABL Credit Agreement, dated as of October 25, 2019, by and among Agent, Lenders, Borrowers and Guarantors (as the same is amended hereby and may from time to time hereafter be further amended, modified, supplemented, extended, renewed, restated or replaced, the “Credit Agreement”);
WHEREAS, Borrowers and Guarantors have requested that Agent and Lenders agree to certain amendments to the Credit Agreement and Agent and Lenders are willing to agree to such amendments subject to the terms and conditions contained herein;
WHEREAS, Agent, Lenders, Borrowers and Guarantors intend to evidence such amendments pursuant to the terms hereof;
NOW, THEREFORE, in consideration of the foregoing and the mutual agreements and covenants contained herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:
1. Definitions.
1.1. Additional Definitions.  The Credit Agreement is hereby amended to include, in addition and not in limitation, the following definitions:

“Amendment No. 1” means Amendment No. 1 to ABL Credit Agreement, dated as of June ___, 2020,  by and among Agent, Lenders, Borrowers and Guarantors, as the same now exists or may hereafter be amended, amended and restated, modified, supplemented, extended, renewed, restated or replaced.
“Amendment No. 1 Effective Date” means the first date upon which each of the conditions set forth in Section 5 of this Amendment No. 1 have been satisfied (or waived in writing).
1.2. Amendment to Definition—Maximum Credit.  The definition of the term “Maximum Credit” in the Credit Agreement is hereby deleted in its entirety and replaced with the following:
“Maximum Credit” means $130,000,000, increased by the amount of any Increase made in accordance with Section 2.14 of this Agreement.
1.3. Interpretation.  For purposes of this Amendment No. 1, all terms used herein which are not otherwise defined herein, including but not limited to, those terms used in the recitals hereto, shall have the respective meanings assigned thereto in the Credit Agreement.
2. Amendment to Schedule C-1.  Schedule C-1 of the Credit Agreement is hereby deleted in its entirety and replaced with Amended Schedule C-1 to Amendment No. 1.
3. Fees.  In consideration of the amendments set forth herein, the Borrowers shall, on the Amendment No. 1 Effective Date, pay to PNC Bank, National Association the commitment increase fee set forth in the fee letter, dated of even date herewith, among the Borrowers and PNC Bank, National Association, which fee shall be fully earned and payable as of the Amendment No. 1 Effective Date.
4. Representations, Warranties and Covenants.  Each Loan Party, jointly and severally, represents and warrants with and to Agent and Lenders as follows, which representations and warranties shall survive the execution and delivery hereof:
4.1. This Amendment No. 1 has been duly executed and delivered by each Loan Party that is party hereto.  This Amendment No. 1 constitutes a legal, valid and binding obligation of each Loan Party, enforceable against such Loan Party that is party hereto in accordance with its terms, except as enforcement may be limited by equitable principles or by bankruptcy, insolvency, reorganization, moratorium, or similar laws relating to or limiting creditors' rights generally.
4.2. The representations and warranties of each Loan Party or its Subsidiaries contained in the Credit Agreement or any of the other Loan Documents shall be true and correct in all material respects (except that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality or Material Adverse Effect (or words of similar import) in the text thereof) on and as of the date hereof, as though made on and as of such date (except to the extent that such representations and warranties relate solely to an earlier date, in which case such representations and warranties shall be true and correct in all material respects (except that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality or Material Adverse Effect (or words of similar import in the text thereof) as of such earlier date).
4.3.    No Default or Event of Default exists or has occurred and is continuing as of the date of, and after giving effect to, this Amendment No. 1.
5. Conditions Precedent.  This Amendment No. 1 shall be effective upon the satisfaction of each of the following conditions precedent:
2

5.1. Agent shall have received each of the following:
(a) this Amendment No. 1, duly authorized, executed and delivered by the Required Lenders and Loan Parties;
(b) the Amended and Restated Revolving Note, duly authorized, executed and delivered by Borrowers in favor of PNC Bank, National Association; and
(c) the fee letter by and among Borrowers and PNC Bank, National Association, duly authorized, executed and delivered by Borrowers.
5.2. PNC Bank, National Association shall have received payment of the commitment increase fee as provide for in the fee letter by and among Borrowers and PNC Bank, National Association.
5.3. As of the date of this Amendment No. 1, and after giving effect thereto, no Default or Event of Default shall exist or have occurred and be continuing.
6. Effect of Amendment No. 1.  Except as expressly set forth herein and in prior amendments, no other amendments, changes or modifications to the Loan Documents are intended or implied, and in all other respects the Loan Documents are hereby specifically ratified, restated and confirmed by all parties hereto as of the effective date hereof and the Loan Parties shall not be entitled to any other or further amendment by virtue of the provisions of this Amendment No. 1 or with respect to the subject matter of this Amendment No. 1.  To the extent of conflict between the terms of this Amendment No. 1 and the other Loan Documents, the terms of this Amendment No. 1 shall control.  The Credit Agreement and this Amendment No. 1 shall be read and construed as one agreement.  This Amendment No. 1 is a Loan Document.  The Credit Agreement remains in full force and effect, and nothing contained in this Amendment No. 1 will constitute a waiver of any right, power or remedy under the Credit Agreement or any other Loan Document.
7. Governing Law.  The validity, interpretation and enforcement of this Amendment No. 1 and any dispute arising out of the relationship between the parties hereto whether in contract, tort, equity or otherwise, shall be governed by the internal laws of the State of New York but excluding any principles of conflicts of law or other rule of law that would cause the application of the law of any jurisdiction other than the laws of the State of New York.
8. Jury Trial Waiver.    LOAN PARTIES, AGENT AND LENDERS EACH HEREBY WAIVES ANY RIGHT TO TRIAL BY JURY OF ANY CLAIM, DEMAND, ACTION OR CAUSE OF ACTION ARISING UNDER THIS AMENDMENT NO. 1 OR IN ANY WAY CONNECTED WITH OR RELATED OR INCIDENTAL TO THE DEALINGS OF THE PARTIES HERETO IN RESPECT OF THIS AMENDMENT NO. 1 OR THE TRANSACTIONS RELATED HERETO OR THERETO IN EACH CASE WHETHER NOW EXISTING OR HEREAFTER ARISING, AND WHETHER IN CONTRACT, TORT, EQUITY OR OTHERWISE.  LOAN PARTIES, AGENT AND LENDERS EACH HEREBY AGREES AND CONSENTS THAT ANY SUCH CLAIM, DEMAND, ACTION OR CAUSE OF ACTION SHALL BE DECIDED BY COURT TRIAL WITHOUT A JURY AND THAT EACH LOAN PARTY, AGENT OR LENDER MAY FILE AN ORIGINAL COUNTERPART OF A COPY OF THIS AMENDMENT NO. 1 WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF THE PARTIES HERETO TO THE WAIVER OF THEIR RIGHT TO TRIAL BY JURY.
9. Binding Effect.  This Amendment No. 1 shall be binding upon and inure to the benefit of each of the parties hereto and their respective successors and assigns.
3

10.  Waiver, Modification, Etc.  No provision or term of this Amendment No. 1 may be modified, altered, waived, discharged or terminated orally, but only by an instrument in writing executed by the party against whom such modification, alteration, waiver, discharge or termination is sought to be enforced.
11.  Further Assurances.  The Loan Parties shall execute and deliver such additional documents and take such additional action as may be reasonably requested by Agent to effectuate the provisions and purposes of this Amendment No. 1.
12.  Entire AgreementThis Amendment No. 1 and the Credit Agreement represent the entire agreement and understanding concerning the subject matter hereof among the parties hereto, and supersedes all other prior agreements, understandings, negotiations and discussions, representations, warranties, commitments, proposals, offers and contracts concerning the subject matter hereof, whether oral or written.
13.  Headings.  The headings listed herein are for convenience only and do not constitute matters to be construed in interpreting this Amendment No. 1.
14.  CounterpartsThis Amendment No. 1, any documents executed in connection herewith and any notices delivered under this Amendment No. 1, may be executed by means of (i) an electronic signature that complies with the federal Electronic Signatures in Global and National Commerce Act, state enactments of the Uniform Electronic Transactions Act, or any other relevant and applicable electronic signatures law; (ii) an original manual signature; or (iii) a faxed, scanned, or photocopied manual signature.  Each electronic signature or faxed, scanned, or photocopied manual signature shall for all purposes have the same validity, legal effect, and admissibility in evidence as an original manual signature. Agent reserves the right, in its sole discretion, to accept, deny, or condition acceptance of any electronic signature on this Amendment No. 1 or on any notice delivered to Agent under this Amendment No. 1.  This Amendment No. 1 and any notices delivered under this Amendment No. 1 may be executed in any number of counterparts, each of which shall be deemed to be an original, but such counterparts shall, together, constitute only one instrument.  Delivery of an executed counterpart of a signature page of this Amendment No. 1 and any notices as set forth herein will be as effective as delivery of a manually executed counterpart of this Amendment No. 1 or notice.
[remainder of page intentionally left blank]
4

IN WITNESS WHEREOF, the parties hereto have caused this Amendment No. 1 to be duly executed and delivered as of the day and year first above written.
BORROWERS: 
 
CROSS COUNTRY HEALTHCARE, INC.
 
By:      /s/ Kevin C. Clark
Name: Kevin C. Clark
Title:   CEO


 
CEJKA SEARCH, INC.
 
By:      /s/ Kevin C. Clark
Name: Kevin C. Clark
Title:   Executive Vice President
 
 
 
CROSS COUNTRY STAFFING, INC.
 
By:      /s/ Kevin C. Clark
Name: Kevin C. Clark
Title:   Executive Vice President
 

 
ASSIGNMENT AMERICA, LLC.
 
By:      /s/ Kevin C. Clark
Name: Kevin C. Clark
Title:   Executive Vice President
 
 
TRAVEL STAFF, LLC
 
By:      /s/ Kevin C. Clark
Name: Kevin C. Clark
Title:   Executive Vice President
 
 
 
OWS, LLC
 
By:      /s/ Kevin C. Clark
Name: Kevin C. Clark
Title:   Executive Vice President
 


[Signature Page to Amendment No.1 to ABL Credit Agreement (Cross Country)]


 
 
NEW MEDISCAN II, LLC
 
By:      /s/ Kevin C. Clark
Name: Kevin C. Clark
Title:   Vice President
 
 
 
MEDICAL DOCTOR ASSOCIATES, LLC
 
By:      /s/ Kevin C. Clark
Name: Kevin C. Clark
Title:   Executive Vice President
 

GUARANTORS:
MDA HOLDINGS, INC.
 
By:      /s/ Kevin C. Clark
Name: Kevin C. Clark
Title:   Executive Vice President
 
 
 
CREDENT VERIFICATION AND LICENSING SERVICES, LLC
 
By:      /s/ Kevin C. Clark
Name: Kevin C. Clark
Title:   Executive Vice President

[Signature Page to Amendment No.1 to ABL Credit Agreement (Cross Country)]


WELLS FARGO BANK, NATIONAL ASSOCIATION,
a national banking association, as Administrative Agent, Collateral Agent and as a Lender
By:  /s/ Eric C. Morse
Name: Eric C. Morse
Its Authorized Signatory


[Signature Page to Amendment No.1 to ABL Credit Agreement (Cross Country)]


PNC BANK, NATIONAL ASSOCIATION, as a Lender

By:  /s/ Robert Fernandez
Name: Robert Fernandez
Its Authorized Signatory




[Signature Page to Amendment No.1 to ABL Credit Agreement (Cross Country)]

Amended Schedule C-1


Schedule C-1
to
ABL Credit Agreement

Commitments



Lender
Commitments
Wells Fargo Bank, N.A.
$70,000,000
PNC Bank, National Association
$60,000,000



[Amended Schedule C-1]

EX-101.SCH 3 ccrn-20200630.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 ccrn-20200630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Amendment Flag City Area Code Entity Address, City or Town Entity Address, Country Document Period End Date Entity Incorporation, State or Country Code Local Phone Number Entity Address, Postal Zip Code Entity Address, State or Province Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Entity Registrant Name Entity Central Index Key Entity Tax Identification Number Document Fiscal Year Focus Document Fiscal Period Focus Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Entity File Number Entity Emerging Growth Company EX-101.PRE 5 ccrn-20200630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 cc_logo.jpg begin 644 cc_logo.jpg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end XML 7 a52243705_htm.xml IDEA: XBRL DOCUMENT 0001141103 2020-06-30 2020-06-30 false 0001141103 8-K 2020-06-30 Cross Country Healthcare, Inc. DE 0-33169 13-4066229 5201 Congress Avenue Suite 100B Boca Raton FL 33487 561 998-2232 Common stock, par value $0.0001 per share CCRN NASDAQ false false false false false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Document and Entity Information
Jun. 30, 2020
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 30, 2020
Entity Registrant Name Cross Country Healthcare, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 0-33169
Entity Tax Identification Number 13-4066229
Entity Address, Address Line One 5201 Congress Avenue
Entity Address, Address Line Two Suite 100B
Entity Address, City or Town Boca Raton
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33487
City Area Code 561
Local Phone Number 998-2232
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Entity Central Index Key 0001141103
Title of 12(b) Security Common stock, par value $0.0001 per share
Trading Symbol CCRN
Security Exchange Name NASDAQ
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 1 95 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://crosscountryhealthcare.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports a52243705.htm a52243705ex10_1.htm ccrn-20200630.xsd ccrn-20200630_lab.xml ccrn-20200630_pre.xml cc_logo.jpg http://xbrl.sec.gov/dei/2019-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "a52243705.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "a52243705.htm" ] }, "labelLink": { "local": [ "ccrn-20200630_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "ccrn-20200630_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "ccrn-20200630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 29, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ccrn", "nsuri": "http://crosscountryhealthcare.com/20200630", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "a52243705.htm", "contextRef": "c20200630to20200630", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information", "role": "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "a52243705.htm", "contextRef": "c20200630to20200630", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001157523-20-000949-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001157523-20-000949-xbrl.zip M4$L#!!0 ( +J+WE![F7Q=QQ4 !]\ - 834R,C0S-S U+FAT;>T] M:U/CQI;?MVK_0Z\S-Q>JL*W66\!0Q1@F0S(#+)!,=K^D6MTM6SNRY$@RX/SZ M/:[(ZM=YO[I;V1_DPXC<#J,XV[WUTRA\VQKD^6BWV[VY MN>G@FTZ2]KNZIAG=,,YR%G/9*OM'8?SECN[8[+-LVOUVJ?^-H7I3S_.ZJG7: M-0N;.L*TM/O[IX^7?""'K+T(#RXO9@/KT-C=HK'J&F:)J5/G+F2+'M,!MZOZ M4B0, "]_?W?Q<=8];^X_Z]K-4Q9G09(.61XF,]. M/[F^=QZW;=!JGG'6[C,VFLX3L,Q7P)0-.,1K:[0V1,@%.E;K0D-#]W&>KB2E MUX76JF,\'C9W%'G:S2,@WY=$ 2KS$FB=L+XW@RCO-TTHQ$V8B(./.( M\'&:RIBO&E>V-E @9B'/FD>IIH:ULI W#X &[$X7NN>C=$5_:,$![OP >-G3E/(VG?7F:9%E)TX%D43[@+)4=G@QA)"J?H97C5FL_ MFJ'6P7_^!R'[,(503_"A//R/G%V?P*(G3T3JTH]5& M]Y+1) W[@YP A!9I$\2%O$L3)M)0]"5IMRN AC)G!#%KRS_'X?7;5B^)?N+G-1 ME=PV L_2&;,"4QBZS]S TG7-T0UF>D*[']0#8 2E)J6:L015=YZ(J0PDFAV9 M'>RCD]S-E/N#J8ERFKN#5*T"*MFNYN_<9J)5-J.)?-O*PN$H D+L=^?G*):K MKZ%^9LDX5;]44+!;HJ,HT(A.V4\JPE6_0H&_@U"F1*TG&UU9[^27>7(L#CZH M7LW//@)J):+Z!:% FA^!FA\@4&W-;AM:-6[6-@53K.A:M52_JT6ZF EW0'Z748!F*1V4D\''?3Y7FJQ>U?D5SI5]U!08KE\MTKW506:9ZQWL, M16$G&LR$#F8"6):-6#PW5=ELHQ51+VXD&L!=XB>1@!&_GIY<'1^1RZO#J^/+ M_2Z.OWN6UL&//U!;VZOC7:*Q-&QAK6+@Y7'OUXN3JY/C2W)X>D2.?^]].#S] MZ9CTSCY].KF\/#D[K)W[;0.L#O$1.B^OU$?BID;D*1#_"']B^P\$D* MLHC6/6*C#/I43U-GD/;]+6V'X#_;>X5I^TNS',;! FNN"6:,!Y[KF Y88#!S MPJ74;]4(7&>F$O4\G6-PU6,_%Q5ZRS0/.8LJ0?>3/$^&4\B+G[M$']V2 M+(E"L0#PE-ZY.%@"I3L'2_6$#E>QXV =QFU S5;JT?NSBT]DI?.IPI8B>)CZ M'$@T-%^S X=*Q[1=PY4&X^ =;<<*?&ZR-7R.V_YEV=G\36798:[KZ\(2.K=, M#C%FX.A4E[XKF!=09KS*\GUL:?(0"X(,QOGB^/2*7!R?GUU4(N)< (YDC-=)E@MJZ95/=]RZ/2==?0\KD@6,#L0Q@P$&PR 6@ABC_X>1Q+ M8H#LX9"'V(-PV"=9RC'4_"-*^DGG_T80OT.^][;53]EH@-EW]X L3E&,_CZM MB,]]/W!LS? #S0P$.$77,*D-_W,,W3)?/>+#V&(^,O"\)U&[D/TPPS)8?@HM M]9124,_6=)T:S#-U#?PDIX[- ]?5-<:IM8;/[&%Q@_2*Z@;Y,"UO[)"3F'>6 MU4?9EX<8NYK$M@ZVCF\!;H4@VI=TBAAA&U\#"/!G-K;!LSX8L[8=Q.RV,#FTV0Z0Q M+[_'-(&12%*("E1M_C('=UR:DEXBZI9*&@:8*H=3GPI3\[CO"-_A1F"C)7)Q M'^(A?A^W#;#JDR\+G'S[Q;$^@YFF!W->&', M>!]&$MI\F=8H3ZE+/6DSX;N^*2#.\B'<"CS):>!JKK..C]#:P#W;^SIT?8%" M?L5N3\IJ'5>"ODQD"&5][CJ^$TB3,>H%.K0(31O\;CA8B6,K!MUO28H;'3"$\ M3PH-D@S#]#P+_MAK$-8P3-=9D5(O:NU6"0ZFR>[AF9)S=5-G_HF M=?UU=-.FBP2XHYKX$20Q.A\D\7)8:S#==6Q?-QS?-2'>0A!\S9.2:EPRMHX& M>I[;UL&PK,N161GFQQ]RIJ'9*ZD(K T81DFURWF:*9AVCKD#ZY%]:"U%+4LQ#!+\?\= M<9[1,3#2;4Z=EF3Y"5R^PF-0Q<8#'Q .S-1O-1J-:>>F!6^5TRA-Q83JOI*GFM,P M)8=P,L -T\!TJ./:NF$%MO I!!]^H*]3+X><+$%:)_S+#AFQE%RS:"S)&ZV# M9WS(" \##1Y0A=J8#*RB1RF"A036B*&;MF-I-M,#EYO@T3UAV88KF0/_>,YZ MQ.A=G+X8/"N^5_NB"WLEW!$!-0U;!(9M'?XWN439()]8^D7FCZ;.RLI-];24;-[A?9>.3+:6 -FL"V]8 ML#>00!5TRFP$T?HH#;'HXR>WQ)=13KHG^J\3X,\@PX(MV9AR7]8FL)L?,AXP.(G!+0SGV M7=_R( 1W( LQI.4&WB/D&(^2^@P(D0,[$)];W::(T8+LUKV,0BF,L8RR2[31 M[5P88W7*K=""-$_Y_]4GW=8-=TN" EGJ%)V+'2_&$':8NE7*Q\)!"SQ?L44= MTGM_0JMGF- MK/=J/35%6V6,:PE"T?>91>$DR\8R;18(ZAHLD('O"LI,&KB>$+;I.I9PA6E) MZU4@GBX0AFR;6WP]@2C[WGE"Y9Z##IN+L$YB@6A!4#4A7$5;0XA!(6V3:EMM M(12"P I("C3!#9,^Z:?)33Y ZHPP/&(9$3((X^(P3N$?-:OA%.+L\*%!MI!I MSI[RD9JUC;6E@J2ZW]:7Q\Z"SZ:CC-/9D,XXP7;G&6EWO((.]]2,JV$_J5&] M8E#=?ON<26[:KDYM$_PV>'%X&,T5"E <;\%B:C6BB:X^$T(2R-W8X ? M6E()D3^, WEG,8=H82:9C*N+?S@*+^,*EHJL2!7$JOJCL<6F]<>Z8.-5"\\Q MS04JK[XGPR/)4G5":[!'RHW-/!E55<+R375BJSQAU\2Z$>O+MI]*]J7- HB' M=@F+;M@DF]NEW1^D5?_R=%.9C2OSW@#++C%'MT7KW-FH05E.TM6X^Z_FE4UX MMG9=RC3(UUIR3IY8F&TJEYWDM#TD:_@6]673%_-9"?<.; MSE5.CI2:WCHLKCZW_2CA7]1^;MT%;GSZ2O&_VAK'ZJ IY/0)8:3*=L@1.IM0 M[6P=]E.I7/43O>FFN=\Z.(O)W.'R'7+WZ5FRA3:@5;F%;<*&A8'"PZV'[S[" M<"G"?(8Q$>H>[QG/$Q\\MF[A.M2#<0D8()RL5QG,;.RC0-&D9J^B"&T/ M+G S2*"IG=R@$\?NH0A9&B*&YZ<]\H[%7\AIY["S@\X^4M$F/,:"?,;]#O(> ME#QI[*4Z,3$$AJ%15DP#"Q.#A<,J6(5D(X)AC)>5,R \8E-<.,]A-'3HH_G' MZ S3==QZ^DM69A3D4>9M_-B"P,O..&7 >!B!!R9!F@QG^+^ANM;1"+ X0F,, M0O:&&K4W'7*(%"H"(ID.@1C@@85R%NKY6H(/R+."$B/PI*JF5.XF-6&4RB&# M$ G;,T"],4CYIE)[IPUAH]_()!6;)EY BD"Q*!]U4X M1LYJ-5TT/_4754D73T2TW[$(OY@R$ZO+@90@;VF*49C25[7";"O_A4E3H:YA M//W>R2S8!.6;QAJ%;H%6]$H+6M[<@O[3 KJJG%<''M5X4*6I8,[I[L9UZHY+ M,#.=>1B1FC3,ZFCZ\TKIWTW1GILM1W+$TGR<*M==Z'&29JBU/9GFZ"B+@TMI MMD>.HS)EJG?=PX,OX*GR2EF7QV$,)..,0?=)7;6SINZ;JA23:.5.Z*05(1/Y[]=G+4 MAI 2B"(D#-BIAY739=XED.@"&#-#.N.EVKZ[1D\-N/P+%A'C@HU =0S1( R* M&' &<^[Y+38Y/;V6E-S9)9\Q+F-#\FZ<8@!V_-NYHD1O$,J@[@&* 3O0+P@F MY/,@S.6L]T^048[(.>"KOJI!/B?I%U@>@I++)!H7A;X?V7"T!UEZ>@T3P4J7 MN1P-9$PNV36 4$YV-I+%Z? B *SYD7$&>@/N):JM*F/H':GP/Y-1$?TND 2" MI=M14:T CF&Q)XS'DF!) 9,>+O'4&#%HE5#@O#< CPK+0F *%L14M,HKJ<=Y M951*?#;F W5W;@#FOXT1+1I]#-"N9=8AQT& .@84_WD<3)?M%C;D4]JI^/3&=/0="S/Z3[!,R8XWANOLJ#0?>TX).WN- MV&'_@HYO#,?%]]^K]_$PZ7_U/B_(^\SLA3J!7*@("EV94=SE#5:;^GKIS7TD MH/.W8,5V#:*'R_XW.I8X5^6[]RMZ;!/-\W'9JI-UQK4?=1-F\8W_*=M<3+^0X+X0$I6P_$1O7?B'H',U*)E_KTMV+D^=G MDLS[H+OS2G8S)38#\(L1O@=@\]QRM^+J_\NW1_N,%-\09):NFX:C6?*6:G_0 MSB ?M@ZPRKC?90=_%XFY&]L-AF"M@^FG+O$")5&UVJ8J[TZYK\%4AKZPA>)/ M5(161F;%3L<]VRK8GY=Y?KG9(1( #$@_M]&!"T(4E"8W4M4@%OF ?_ICA@DV M)+:/WQ9IV@O9*3X)D:L,L7R#LQ0SKBUOC])I0!B)^;9%%T/WI^KWZIF?R<(_ M"::5*OD\0'WWO-JP=:":V:%-F5]SKDCN/%1&:^<,+'.4-UQTKE3HKELICQ:9 M#=.FE\ BY!P, Y@T-!)%E>:(Y8RH*_I;6!D26/?'TRKE!N.)HA?!;Q:#Q2N^ MM+:]"N$&<:R>'O=)GDT=3;GG<$K#V92YTREWGSY9.+ORZ.,HEL^FK%^1 M*B^NS%.)/KV,T'Q-\N2GT\.K7R^.'U_A*&!;X*"SB;)'_3N'17G[SW&8SDKW M:WS?L*A67\P?!Q-8VN1LK#Z7CIMBQ5758C=[)D09( P]DF(/VY<#%@48?>", M:A.QZ+ #$I/*,6Z6J8G9.!]@-4R*1]4IOZ=:C<$MYGHVIZYFF3Z3GK2$SRTA M?,,69K"A[Y#9'5UO,++#4(A(ON3\:C5*IM[1Z'>/$PA%X16-J11^^WRFT?>@=7AQ#?G#:ZWR]9/E5D+\#G)J"Z.\+GZEB MZB](,;]^:>I5V[X#G%ZU[=MC\WS:]DVV7[!VN/M,JO8M$%KX0/G&U>VY-E;> M39[*!7W5!Q/7_OSPU^54-^M.#RC]7)Y]>2H)S(?6]%Y]YS_9=[YP5_,=.$[\ M#DQY@.UQRORJ@*\*^%T@\T(54'V%:[?V[4'"7X&"7&P F\\ !, !A-3(R-#,W,#5E>#$P7S$N:'1M[3W] M<]I(LK^_JO<_S'EO[Y(J[ #^C.--E8*QS1Z!/"#Q2UU=70W28+01$C>2[+!_ M_77WS.B+#Q,;').0VFR0-)KIZ>GO[AF=#:.1]_9__X>QLZ'@#OV"WY$;>>+M MV2OUK[[YE]U=UG1MX8?"85%PRM[%H>N+,+QSI5!MZ,]Y8,_ [9ATX;?@IVO%?>J^R5,V_7@O%$NC?#B%5>OSYDNZQ:KI;9 M.QEP1[K.C6"[NPK>5QK@LW[@3%C_Q@Z\0/ZV\\N _NRP,)IXXK>=0>!'NP,^ ML$(^[_O<3H3HF%0KJ#-XQ:A^Z?XI15RN/H#8O$UVB7 M>^Z-?\H\,8 [-,XI^Z5,?][L*&@<]S9!'N_#S&SA>>&8VS#=WW;*.W0]YHYC MKON!=(2DGZ[SV\Z?!Y6C\HG#R\[K8_O /NJ?'#B'5;%_XAQ4CQW[Y&A5$RJ MS^Y<)QKBP_*O>B[X)UV0LTB^S2P/7#L&$OWJ87DO_[)NB"CYVR\PK3=GKU+T MZ(>O(N?AW9J6V<4AFH'69SCC'*[N!#XZ!8Q[#C10(-6_#MV^>P-4!@1X]@H; MOCWKR^)@]P$.E[* -+B%!&"H 3M@:<_9'N]]9CJFBRQT>;B6>#P+8\#)D9!O MV(C+&]??[0=1%(R $JI()H^C,EB&^*WUOMXZA[\]UFKOL0KKM9GUKLEJG?IY MH\>LRTZ]CD_/7L5OEP-8\1_=<7T'H#]E^T<([%IFL"3X)>:0D.,A"P;L]]@7 M;+]<4E+K131T0_:W7TZJU?(;"V2B0W*Q%4!_=+?RYF6)09/^A'$?^A@%("BO M47*D)'8!DPO8.^Y_*;$6C]S YQZSPC"P7;HJ,7)D-1F$(9@IL1_)";L2W(N&-I>BQ!J^O8=S.1<>OX,[ M *H8DUF[5\QYX[B[O@Z4'O&4'HS'W)\DPT]VD0_0D MOQ6>&ILZ_\:^L^^GO;X7#HR282*P3R.0?(8 40E\^UBZ5]U9.EK[NON0[N"U MM _44MA_:'.?-1I)?S70@R"S?9SR(#S @7-%G, M/8\T<%[*"!N5I0="X8_ ]2/5! R&6Q0+7E'\:> RA'=NL2NP.='A69()LZ]D M&5R@M<,^H:D"R%7B'4!1WAA*RZZ0MW#Q(%*>U?U\B@$04RP96%>TPI'T.7K UU?U3MT">X8LX))V#.&-5!.C MU,Q([2%8 HRDGD#!"U(]%+X+QE8H[%B2EQR*:+?/,80HQ6W@W:+VLN&1&Z5J M90"V.*FJ<2S#&/H&'<3NABX8ZAH&]@(M.#+_01?VQ9![ _1?]>.7"I(1=P2! M..(3^/L%M&' ?>T!.+>H6M3%6#FT+" ]!Z8./'+1P0 5-!H%#NG$$*'(3!V< M"D%.-+H8/FD,"A#09 X*<2(\)8-$+3!*D)?NWJ(,8+*ZY+V_=/)JR# TBA_ MP4D?LI"#3G7A,8898#A4D3JL@+,?R&#$(EAPG 3]FU7(;!!+FKI^N\1@TF , MX*\P'H\]F@E> >GI%F XBCOU(XQHAK D4HP];N/=C (M8L2HT3?/FN@7$[D4 M_XEAWA@)1^M&D2+99)I .;"9[L.X_P<8.&8893,IR\=7QEF(/Q$J32BN_[S78FEN )DCR&1E M AD:;<B@W2B.8@J3:+HR5' K0,!%TT10RDLB)0UO@L"A]VZY%ZO41G9TQ>E2V,(= M*W(-8W 6;1>0/T'0E-Q&VC4BR?[B!W>><&Z,G#"N@/$$B+!!K@W 4@_NPG4H MQQ4;T)4]DT/(]@K>-XA#Z,#U@6G%;M\+["\%$,OCK_E%QVN3E#D91RH]U.M< M=CJ]BRBXZKUO]GA_)\FL3(_Z:--DQ7;.N0"%JL1.QN)9Z2@)]LT_SY]>"A1C M>V :_;9S%4CW3^1*#Q>YD!%[G0R4(979-+;SEFT":5AIL. IJ$3Q#.LENC>C MRDTSF]ESB1P\^[ M'RX^\!OQ#JRR+Q;\+UE]VQ-<8OHR&B:T&05C@X0BM2JED4E1SAPAZ7T,=W;[ M>&N7K,%3QKT[/@D+B=>SH81)AT.PJ'_;T3^2/E0N>U>3*4FT&4"?LH/Q5_4T MFW0&M*O\;)7>*Z2G^Z M;F00^\[N5.*]@,G\U5]V=W61 'H<.3PF*P^ M&*C8(SN':>37EB2(*\.(%H_%8Q VRGJB+*TV\S)&?,[_[&*_\,8A-$S7D3+0 M12#(@^D+X'^HX#8.BXLSL)0_@WRT8ZOZ\JK6Y5*:C29(U!)*3* M%"FL4GWSGG]U1_%(RXFG4+"I C2$BXZ6"0GDX3%LH*,H"W2S(SP1*1+%K"X\ M=,%EF&AYHL1!FBU(U/']*O@!1(W/GT*$S,:5$AE_K>R72Z -Z2^:*R!T,;8& MJ$($@&R/,40V8)CP:>C'*BZ6R["D H.09V1)=:]RH)8/I8A9CXT0"OM;H1"_ M;6 H=@P<0C;JNMG^ E3(.);C(!1A2C5YW0,F@.?IF$L<)I&'3)0 36N*/-RY MH18CF0"%LLC1PN['$;4U"!B.97:M8?"B3W03KN5=3-2=BRC M/5>B%"UM?N<&0!2\470JP]HM*8$Y+.)B427\6(2[Q9"5M+XC0$@540X.*U0$E[YVD&&2 M%&_GH<'G8K1L'-L>;-EV+MMV!-AM(4Q6Y9Y+[)HJDRE/@L11,UF<=?-V'6,/ MS8#[6"P8S:^8D@9@!=^= C=4BD?5DE/Y=>AO3%?*%D\##3,&0DT4N1'T#L0#RW?#0:_Y55OD>*&<5,:*!1OX)1C=M@2G3T Q M<\#8:3\MVT2$_"=VU9ZRL005YHX]05%6>(3%\C(>1_8$/:,P\&XQZXJ\&,@; M\&/^U-IFA(6F0#/QJ(1OAM"YQR7S^%V8G;D4'H]T=0$T(QC2^IQ AG]7VZQ" M!GRL^'YO@WCI^\4)'\5+XCZ1B*9)@6E@]9#2NG$?C#*72VR69OOGQ=G@+8P3 M:6-#I?^I4[.E,TRME4C&0I<32(G5)DCLGIA^R%IGGB%F(A MTP:KO?X38X&["X.J4="[Q^3!>.RY-C$ %@< @/?@@WKG'MAZSH1""J9CRAJ8 M9 /R3W9T>/3> &PY(([ 4%3VE8J- QL3J@WSN*,QF(\O#3*1J+.3US7*+YG. M&*9&7&)!8@4S)5&"^&:H@G*YQH0@:IW@+= :+R*O-,'B/0@AOA:T'DAJAVRIY,(C(WV\3)]3A%"=O)YFO@I" 'F6EA^(HF4#C)KFL7]RTV2H.L. MJBJUGOU_=JOMZH5KBU(E//9(]M5OA0J6FWMI1A.-E\"V8RFUR>(J>>KZL=JL MEF-N8FQD8\I_WKA4Y"H4":DPY;39LCED<+CUVN9Z;;4T.?L!:^(<%1->CX>F MC>!U=#W3L$Y$ODC"#I2C5E4 F$CFMHG^9#/6:55,FKO.^VIC@ZOG5BNCZD9R M0\S8X6/H:/K-59W:0#?,009^($?<,ZVP_^3>SMOJ3-3]M&5 SU)^;J13KV(W MF<09U?QBOKS@+S=P.68G5RFVPF-P*0!X54(U+\Z"J]7! MV )>)^$X#,T9-Q),Z#>;LXK]S5Q%D23E$/<=4][6239'M0)TT+YA87/[I ?\ M-J"3/18G)&BK[.:LM;VI:YTFF?+EE]^6/'H(,6R2?[&1@;I[83T;: MY5R4J@3OTFQ0Q"-[IO*5WT9*67,N ^ FT8L^]$V[#!_.[PB$:"" CFM/3FV,">.G<9-,#B#9K9FUN_.!;ZSHBCRU)8D2-#0?F&QNVS:M.H!PZ\HH M%F9,TAPA(5"+G/S0)_SHK%EL&[V%(\X:9PYTBO)R^;R%- 8<>2Y-LXF MNL,D<+KS=DY7"5IFI:%*2[RO,(B23@;>]-:O A9R6Z\7]-=']2V9 VU!&V;))OQO"X M@SR3(V<\CPG: R)-R3BE>TMLC :%VG(#=#YA,9T0N#"'.+UJ&U>>=+S5.',U MSF4 5(*%TJS)[YYB/PD5<- )?6ZNJ%UQ0J: 8I$\0I"A+];J@.Q%([\2/)D0LC4'DE5:Q!.<2DAKU03IC(D1M"81J, MH7FAVX!E&0:D;J2-1433YT!^H;IW\=54P>.,LF4AJ:BE"^@J@85)K/C5-RDU M>A?$'H@Q'H>JDDHG6+,5G-2!D@5_Q( QQ]4A?NH1>O%-L_D@;QSCGVP9?R[C M_Q[+">M1/>975N-3_4N//[,.HW+JQZ>W=OK-*PF@X>_?^Q\9NT+>EIK6HWW)79> M?P]=0:^U7J/=8NT.JUD?NW5JI6Y9G4:WT;ID'W$PUKMJ0.^%\X'AK4:+>KVV MH.=VJU6O]>KG[+K1NX*'>2'0J3U0$O!$XZ)$Z#?-H0^8,@Q8Z\%*MCOP__K_?6ST/D]-O8WM MKQO=^MX#5I:.7>[28QBN"TV[, VK1WCO?L1)++NDW2NK"02!Z,8%.$?:J+4_ M=GJ:5'#=VA^A9T4Q."2-1. D,'\V$,,("F#V'I;_HM&LPRMPMW'9:%G-PJZA M]L<68!+?)X#@QH?/3"(BHE:"SNNRZT^CUZK!JGY!R:G5#*!HE<^A&4QW:73F<,C&R>S76YD]5V:_TR6O*DRP?FMMD?=DRF^IOJ>IO$P2I MLGC!H9R*58/E$]KJ+OEI!&ME##X\.5YCG^NH]!>DQ*]RC(SI+^L2/ M$BZ-/01*53%4[,SU]3$K:GIV![TU4KBD_?9?"8#IO98X.27.2VKU5.R/, M_HF[83#2A;\YU!%D9H^+GSB(\5M!H!0H3DIA &?CC)?*TU8$ M_<0(9LV(]6M^R:;P]=F5Z2%I3IJC0!,(3[0M-M$E MF#PT7(]Y9'C2QP1&8SWM*4& M/S'CU>E4@AE\9S('ZV:[)RN3-HFK&9D R1R8G%%,X/5QJNJ4D M$H]F"J4NP?B(A+]YBWDN:5U3#R%5(1>0^*WP M73JEFFQKXJV LOZ9!*TB^5#;N&G2&8][,:DPQ28_@D(^V#+"4VU5BHEZ0$^L MG1F>2O>65(8WL9(3'U1E:GU]K)TYOB7)"0/'X=>3"N>^)'6TIMQAUH#:RLYZ MN^IH/M#&+]R7M-46/S40!3TS XJ>8/-32Z9&%PJ&/SM73=[KF M':H!N?2"/IKY 'E29UH#+2NP*L3"1#25)H%% 6I484$'43_Z^/6P4;;K'BCJ M4'D,(;U<4,S96@X)T[CEVC3);,6=-;L0$\)O8/X* !A$@1V,<9=N\=W<^20S48P%4M_6IW+%\DA M24U57<;W24Z-HY-OT[H$.FDB5Y2#7]T$,TE_=PL6+_DH 7Z2]O1)*6A8 MR5NACH;5M3CZE"_ZMB,:8BC]Z?SI ^;$&,\^U?X$YIKLM]./Z)S*'0Z?S;* M_.5*Q"AV;_@FPRG)&2_S669AFJ# D$OQX!0+NAJXV'S5U,Z(NE*26% ;WI/$ MA(/VKZ.U;#'$959*!<+4)R,SG9K3J\RGTDI9_4VJ'I19(8RKWUOC8M#'I\_=4O5??2+!M!Z1A^E9.32@HDAODD?#/ !G A-( M#<>#C)"U?CSMGZJHSE'D02BE&E(E3V&YT 1B?8_[7_XU']R'Y(;FI)M^K)31 MP:*4T;S\D$D/S<@I+9\Q6IP1*N23'IPBRF6A5I M[3+ZJD[[8N:G5TBW44'8G"I8)1X7'>%$Y<[9 \BQVEGY-A/ FC[AG/<#&"EU MUY?&V8H-X7?M3J=]7>]T3V?9J(\M'ZA6CI:M'\AC0)WW9./GD_'#Q/[-;SOE M';H>8ZQ77Z^&KW,L,DVCQ?0HS>;/PY-ROR*.3ZK5D_V#BGU\(L3)X9'8/ZX< MGQP=.D=9GLUQ;R3?YG7*6>04'*Y#! 2(*<*Z>P,,"-:,>Q4YC^FE&(-)4.^"E^Q?X"=[+/:'JMY7'Y)."1>L0_<+Y*B$M\T6@ML^],B M($\V>@^W>YQFS\%AM7I[UK)/L0+OSLI=F1 M,^CWQ6&U[!R^/A 5^^2UPRLG1R>'9>Y4A7"VTFRA-*O__@^+=>M6IW9UGP1[ M&KT^$TS#7%L9^K/*T+HZ*18,ST\8MO@@!1Y9C:G'!RC<^R3O,Y8.WXT%EC"& MNCWKXH+*R[>FT):-OS\;+S*@-MKF&9SL[_=/;/ZZ.9;?:]$=DV87F_^S,YJPL M]F-ICN61M"BQNH[ABTOTSZ0FB6&6=NH3U&00AHR*S^3D93&[_KVW M9_XT>Q@WU'7=-)_T>:G55OV:O:^?-[HUJ\4:C7M4[#94/TO)/XV&_WFU^PIT M^JH:/"EO(E_6K"8[;]=Z[0ZSNMUVK6'UZO<9PELNW7+ISVR#;Z8=HT+PKX]. MRHYSP \/^P<'E6J?'SF'8J32G5-YL[3\NCE1ZMCM4"F88G=$HO_ MC"*E3 M_O#4N4:MWJ*S_KKUSB>XV,1(Y):G-X>G%UDW^6T-4QMO%Q9D+G[WZ6*'3Q@K M7/^^G)]W\\IC2'!:\NG>\,(4&*]GW\NZ?>#K>K/991=6Y[+-WEFM?^1VT+9( MK8!3;[QYN-)"I;1&^:6'X,PW&X3Q.^'J.Z69KPCQD%G.R/7=,,(3MT"8T=;- M$C"^1"KWH'SR2_=><'.S'@,;0?D_*N2]=&M?D^ MD*'([O1_5LM(.OY[?=;G$7 7L/O-F)U_S,;ZA6,C A&0?$9,'S00R,EZM,#] M[VZ-D:TQ\DR,D>=N=]!WW=#>6&ADI*N]4'VO$G-;[?ZTVKT3](6,V 5^.@16 M]\^M@E^Q@I]&\ ^JXQ^QP?/QC[/!A&BLKE<2:9=&;Q5\FQW>T=U*]!RL+9VP:R43T+VJU M",%/C[L<*ZXK%_N#TMTU2A%V 09"8#XOOF?-+'S8TN%]N/SK<;D$4A#_?E\Z M-!;H([#W3,F5HB6*3$U*Q$I3(6LE6W,2&!K%^A9UH'SH1^#*.1!S_^"U!+ P04 M " "ZB]Y0=R\;F%,V "P>0 "P &-C7VQO9V\N:G!G[;QG6)/=MN]] M([T7Z;VC(+UW%>D/H""@M(C4$"'T#E&J(D5 0+I(ER;2>P<1!.D2>N@]H8:6 M')ZUUUK[7/O:'_9YW^MZ/[R'?T(RYLVXYV^.D80Y)DDF]@]V$:#2T=#6 '!P M<( 7UQ< NR2PI^X+M@< /3U $ (H ( 5N75O\UXV7.#0 [K6-05Q,05R<4TQ604)604H> @^X/ZK*J%F_8#W;ULL(?X?-JZL. D)/RG M_1GG/ZN;_ZQZT?_=^B_5AHR"F/A_>^Q:!#BX_ZPI M"*YOF '\?]@ ]4<^P?[ R@!A 1$! 2X!,1$A(2$Q.1D-&2DY&2DC'1W*:D96/F8&=C9F7EY!41 MX.2^Q\/*>D?V[CTQ<2DI*0X!>64Y"24122F)OSO!(28F)B,E8R0G9Y3@8N62 M^#\6MAV@)@*T@05<'"[@%C4.+C4.MAO@N!XE/LX_]*_DX=S"Q<,G("0B)B&] M=JBANHX8%_<6'BX^/MYUL#A!U[\'\*CQ:;C$'Q#(YV%E M!YWA"))7\J5["#$)/0,C$S,?O\"=NX)2TC*R65U;W]C<0AT<'AV?G*+/ MSO^.Z[I2Q/F7_MNXJ*_CNH6'AXM'^'=<.+=\_G:@QL/G$B>@>?"$T-KM-K?$ M&R+:A_$YE1W$/)*&2+J7[B,D]+Q22WRHOT/[1V3_L\!"_A]%]N_ _C,N.$"& M>_TDI,:E!E2!T_,[P)?7)/]Q@W/G%X[KE]?T":_)1NX3./X":!_?&KF/3PL\ MN4_\0&Y="B<=4K%IVAC=&%1S)#'W2 )58AMG%KO?#=<+[S*?LSPSK#!VG+F4 M+W6PRN#Y)9 SQLH&-HC7M/S9U]O*;M48A046R#&TE>BIKN\_J+VT'BC+KFJN MJ3_L&4D>G%[]E%>^Z*+)_3,*]VJ_ MLI.?%)3!5^!Q;8IV4^/DT9D%;W)%0M>AJNA%%^ZXJ7F&Z,YN#KUW?1LUU$L< M84GP<^!Q8Z5YS9_.NR2+547]P&)\6OT\#HH[QS'0+=@6=Y6\#>_B\J@AATAC MZY14YH\O9<_I%+U93VN#Z*?SQR)CB[9%LXRL-KQTVPO2F;?MPY "WN527OK!1KSW)-%T4,(PED')P,%BOX]/*IN; M+=74_SPS$$KX&8 _9*[R&15[5&A"HR_\C-9JS?2=EYYYMXH2.VWE>&PZA!ES MH"X'IOC=5T"\N AH>A@:( >,OK^==<0(M#)$2>"5/VPX#^U#D)LJ@=75RSI_ M;7FSTSI[5=]I6^+2&D73J#R4,*U\Y+D@0[M@DR;I_=XO]\+D8]+=_3-3?I&ZJO#DG6.)#(Y)2,E.C4-ZWJ&9 MA::;,X^ZE',#&P5)VM&

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end